Abstract
ObjectivesTo assess the role of high-mobility group box 1 (HMGB1) in the pathogenesis of vitiligo patients and its relation to severity of vitiligo.BackgroundVitiligo is a chronic inflammatory disease characterized by skin depigmentation caused by the loss of epidermal melanocytes. Its prevalence ranges between 0.5 and 2%. The pathogenesis of vitiligo is poorly understood.Patients and methodsThis is a case–control study that was conducted on 80 participants, who were divided into two main groups. The first group A included 40 patients with vitiligo. The second group B included 40 age-matched and sex-matched healthy participants as a control group. Blood sample was taken from each participant for measurement of plasma HMGB1 level by the enzyme-linked immunosorbent assay technique.ResultsThe result showed significant increase in the level of plasma HMGB1 in vitiligo patients (79.48 ± 110.5) compared with controls (51.70 ± 69.16) (P = 0.040). The result also showed that HMGB1 concentration was not correlated with clinical parameters such as age, sex, disease onset, duration of recent aggravation, or percentage of vitiligo involvement.ConclusionOur data provide insights into the possible role of HMGB1 for the pathogenesis of vitiligo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have